NCT03829046 - The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

November 15, 2021

Study Completion Date

November 15, 2021

Conditions

Atherosclerotic Vascular DiseaseType2 DiabetesMicrovascular Dysfunction

Interventions

DRUG

Placebo

12 weeks of treatment

DRUG

Evolocumab

12 weeks of treatment

Trial Locations (2)

Icahn School of Medicine at Mount Sinai, New York

St. Michael's - University of Toronto, Toronto